Stay updated on Sacituzumab Govitecan in mCRPC after 2nd Gen AR Clinical Trial
Sign up to get notified when there's something new on the Sacituzumab Govitecan in mCRPC after 2nd Gen AR Clinical Trial page.

Latest updates to the Sacituzumab Govitecan in mCRPC after 2nd Gen AR Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check16 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThe webpage has updated its date references, removing older dates and adding new ones for May 2025 and September 2027.SummaryDifference0.7%
- Check45 days agoChange DetectedThe web page has been updated to reflect the latest results and details of a study investigating Sacituzumab Govitecan for metastatic castration-resistant prostate cancer, including new reporting dates and specific eligibility criteria for participants.SummaryDifference7%
- Check59 days agoChange DetectedThe web page has undergone significant changes, including the removal of detailed study descriptions and eligibility criteria for a clinical trial on Sacituzumab Govitecan for prostate cancer, while adding new identifiers and collaborators.SummaryDifference42%
- Check66 days agoChange DetectedThe page has been updated to reflect the submission of results and has been revised to version 2.14.4.SummaryDifference0.2%
Stay in the know with updates to Sacituzumab Govitecan in mCRPC after 2nd Gen AR Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sacituzumab Govitecan in mCRPC after 2nd Gen AR Clinical Trial page.